Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival

Sultan Acar Sevinc, Seyhan Metin, Nermin Balta Basi, Jonathan Ling, Ayse Surhan Cinar, Sibel Oba, Sultan Acar Sevinc, Seyhan Metin, Nermin Balta Basi, Jonathan Ling, Ayse Surhan Cinar, Sibel Oba

Abstract

This study compared the course of coronavirus disease 2019 (COVID-19) in vaccinated and unvaccinated patients admitted to an intensive care unit (ICU) and evaluated the effect of vaccination with CoronaVac on admission to ICU. Patients admitted to ICU due to COVID-19 between 1 April 2021 and 15 May 2021 were enrolled to the study. Clinical, laboratory, radiological parameters, hospital and ICU mortality were compared between vaccinated patients and eligible but unvaccinated patients. Patients over 65 years old were the target population of the study due to the national vaccination schedule. Data from 90 patients were evaluated. Of these, 36 (40.0%) were vaccinated. All patients had the CoronaVac vaccine. Lactate dehydrogenase and ferritin levels were higher in an unvaccinated group than vaccinated group (P = 0.021 and 0.008, respectively). SpO2 from the first arterial blood gas at ICU was 83.71 ± 19.50% in vaccinated, 92.36 ± 6.59% in unvaccinated patients (P = 0.003). Length of ICU and hospital stay were not different (P = 0.204, 0.092, respectively). ICU and hospital mortality were similar between groups (P = 0.11 and 0.70, respectively). CoronaVac vaccine had no effect on survival from COVID-19. CoronaVac's protective effect, especially on new genetic variants, should be investigated further.

Trial registration: ClinicalTrials.gov NCT04956562.

Keywords: COVID-19; CoronaVac; SARS-CoV-2 pandemic; Sinovac; vaccination.

Figures

Fig. 1.
Fig. 1.
Details of the patient cohort. Patients admitted to the intensive care unit from 1 April- 15 May 2021 were included to the study.
Fig. 2.
Fig. 2.
Intensive care unit (a) and hospital mortality (b) if the time for seroconversion is accepted as 14 days. Solid line represents vaccinated, dotted line indicates unvaccinated patients. Mortality between groups was similar at intensive care unit (P = 0.11) and hospital (P = 0.70).
Fig. 3.
Fig. 3.
Intensive care unit (a) and hospital mortality (b) if the time for seroconversion is accepted as 28 days. Solid line represents vaccinated, dotted line represents unvaccinated patients. Mortality between groups was similar in intensive care unit (P = 0.34) and hospital (P = 0.76).

References

    1. WHO Coronavirus (COVID-19) Dashboard [cited 15.11.2021]. Available at .
    1. COVID-19 vaccine tracker and landscape [cited 09.06.2021]. Available at .
    1. COVID-19 Aşısı Ulusal Uygulama Stratejisi [cited 09.06.2021]. Available at .
    1. Weekly epidemiological update on COVID-19 – 8 June 2021 [cited 09.06.2021]. 43: Available at .
    1. Summary of Clinical Trial Data of Sinovac's COVID-19 Vaccine (CoronaVac®) [cited 09.06.2021]. Available at .
    1. Tanriover MD et al. (2021) Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 398, 213–222.
    1. COVID-19 Rehberi [cited 15.11.2021]. Available at .
    1. İnaktif Pandemik COVID-19 Aşısı Uygulama Kuralları [cited 24.06.2021]. Available at .
    1. Effectiveness of Inactivated SARS-CoV-2 Vaccine (CoronaVac) on Survival at Intensive Care Unit: A Cross-sectional Study [Internet]. [cited 26.11.2021]. Available at .
    1. Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac 2021 [cited 08.11.2021]. Available at .
    1. Mallapaty S (2021) China's COVID vaccines have been crucial - now immunity is waning. Nature 598, 398–399.
    1. Jara A et al. (2021) Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. New England Journal of Medicine 385, 1336–1339. doi: 10.1056/NEJMc2112423.
    1. Naming SARS-CoV-2 variants [cited 20.06.2021]. Available at .
    1. Campos KR et al. (2021) SARS-CoV-2 variants in severely symptomatic and deceased persons who had been vaccinated against COVID-19 in Sao Paulo, Brazil. Revista Panamericana de Salud Publica 45, e126.
    1. Hitchings MDT et al. (2021) Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: a test-negative case-control study. Lancet Regional Health – Americas 1, 100025.
    1. Liu Y et al. (2021) BNT162b2-Elicited Neutralization against New SARS-CoV-2 spike variants. New England Journal of Medicine 385, 472–474. doi: 10.1056/NEJMc2106083.
    1. Vaccines highly effective against hospitalisation from Delta variant [press release]. Public Health England press office, 14.06.2021 2021.
    1. Tatsi EB and Filippatos F (2021) Michos A SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence. Epidemiology and Infection 149, e237.
    1. Turkey: 85% of new COVID-19 cases due to UK variant [cited 20.06.2021]. Available at .
    1. Over 90% of COVID cases in Turkey are Delta variant: Health minister 2021 [cited 08.11.2021]. Available at .
    1. Hundreds of vaccinated Indonesian health workers get COVID-19, dozens in hospital 2021 [cited 22.06.2021]. Available at .
    1. Jantarabenjakul W et al. (2021) Short-term immune response after inactivated SARS-CoV-2 (CoronaVac(R), Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria(R), Oxford-AstraZeneca) vaccinations in health care workers. Asian Pacific Journal of Allergy and Immunology. doi: 10.12932/AP-250721-1197.
    1. Cerqueira-Silva T et al. Influence of age on the effectiveness and duration of protection in Vaxzevria and CoronaVac vaccines medRxiv 2021.2021.08.21.21261501.
    1. Zhang Y et al. (2021) Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases 21, 181–192.
    1. Ranzani OT et al. (2021) Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of COVID-19 in Brazil: test negative case-control study. British Medical Journal 374, n2015.
    1. Indonesia's Doctors Got Vaccinated With Sinovac, and Got Sick 2021 [cited 27.06.2021]. Available at .

Source: PubMed

3
Abonneren